Integra Trials is a specialist clinical trials site in Perth, Western Australia, delivering integrated recruitment, screening and trial execution from a single team, backed by senior clinical leadership and the operational infrastructure of CIS Clinic.
Mid-stage efficacy through post-market surveillance
Operating from CIS's Monash Clinic, Nedlands
Recruitment, screening, and delivery in one team
TGA-compliant processes; Bellberry HREC-registered site; site operations fully insured
Sponsors come to Integra looking for a site that can recruit the right patients on schedule, deliver trials to a high regulatory standard, and communicate clearly throughout. We've built our model and our team around exactly those needs.
Most sponsors stitch together a recruitment vendor and a separate trial site, accepting the handoffs, data inconsistencies and patient drop-off that come with that structure. Integra delivers both functions from a single specialist team, meaning every patient who expresses interest is screened, enrolled and followed up by people who already know the trial inside out.
Our Medical Director, Prof Roger Clarnette, is one of Western Australia's most experienced principal investigators. He works alongside Dr Philip Currie, a practising consultant cardiologist and CEO of CIS. Sponsors deal with senior decision-makers from first conversation through site close-out, not a sales team handing off to a delivery team.
Integra operates from CIS's Monash Clinic in Nedlands, a fully equipped, multidisciplinary clinical facility with established patient referral networks across Western Australia. This gives sponsors a real, operating clinical environment from day one, with no facility build-out, no infrastructure risk and no learning curve.
Trial execution at our site is overseen by senior clinicians and researchers, meaning protocols are read with scientific care, deviations are anticipated, and data quality is treated as the responsibility of the operations team, not just the monitor.
Integra offers end-to-end site services for Phase II–IV studies. Sponsors can engage us for the full trial lifecycle or for individual workstreams.
Protocol feasibility review, site assessment, regulatory and ethics submissions, contract negotiation, and site initiation.
Recruitment strategy, community and clinical outreach, pre-screening, eligibility confirmation, and informed consent.
Visit scheduling, study procedures, investigational product management, source data capture, and adverse event reporting.
Source data verification, query resolution, regulatory inspection readiness, and coordination with sponsor monitors and CROs.
Real-world evidence collection, post-marketing surveillance, registry studies, and long-term follow-up programmes.
Single point of contact, structured reporting cadence, transparent communication on enrolment, deviations, and milestones.
Integra delivers Phase II–IV studies across a range of indications through our partnership with the CIS Group network.
We assess each enquiry on its merits; new indications are welcome where the right patient populations, principal investigators and sponsor arrangements can be brought together.
See current trialsWe treat each enquiry as an opportunity to assess fit honestly, not a pitch to win. Indications outside the list above are welcome on enquiry.
Through our partnership with CIS's Monash clinic, Integra operates from a fully equipped, multidisciplinary clinical facility staffed by experienced clinicians, nurses and allied health professionals. This means sponsors gain access to operating clinical infrastructure, not a facility being built out for the purpose of delivering a trial.
CIS and Integra Trials are independent organisations with shared directors and aligned standards. Sponsors contract directly with Integra; site-level clinical delivery is supported through CIS facilities under formal arrangement.
Learn more about our team and partnershipIntegra operates to the regulatory, ethical and operational standards that protect patients, satisfy auditors, and give sponsors confidence in the data we deliver.
International Council for Harmonisation, Good Clinical Practice — the global standard.
Compliance with Therapeutic Goods Administration requirements for clinical trials in Australia.
Our facility is registered as a clinical trial site under Bellberry's Human Research Ethics Committees. Each trial requires its own HREC approval before any participant is enrolled.
Aligned with the National Statement on Ethical Conduct in Human Research.
Integra maintains clinical trial site insurance covering site operations. Each trial additionally requires trial-specific insurance arranged by the sponsor for the study, investigational product, and participants.
Source data, regulatory files, and SOPs maintained to support sponsor monitoring and regulatory inspection.
Whether you're scoping a single Phase II study or planning a multi-trial programme, the way to start is the same: a short introductory call to understand fit. Here's how that typically looks.
A brief email or call outlining the study, indication, target population, and timeline you're working with.
A 30-minute call with Integra's clinical and operational leadership to discuss fit, feasibility, and any specific sponsor requirements.
If there's mutual fit, we move to formal protocol feasibility, costing and a draft engagement proposal, typically within 2–3 weeks of the briefing call.
Integra team handles every initial sponsor conversation personally. We'll be honest about whether we're a fit, and if we're not, we'll tell you who is.
Request a capability briefing